Pfizer Inc (PFE) Up 0.84%; in a Downtrend Over Past 30 Days

The Hourly View for PFE

Last Updated February 16, 2021, 12:40 GMT

Currently, PFE’s price is up $0.18 (0.52%) from the hour prior. This move is a reversal from the hour prior, which saw price move down. If you’re a trend trader, consider that the strongest clear trend on the hourly chart exists on the 100 hour timeframe. The moving averages on the hourly timeframe suggest a choppiness in price, as the are all in a mixed alignment — meaning the trend across timeframes is inconsistent, indicating a potential opportunity for rangebound traders.

Pfizer Inc Daily Price Recap

The choppiness in the recent daily price action of Pfizer Inc continues; to start today, it came in at a price of 34.72 US dollars, up 0.84% ($0.29) since the day prior. This move happened on lower volume, as yesterday’s volume was down 17.3% from the day before — and down 33.27% from the same day the week before. The daily price chart of Pfizer Inc below illustrates.


Pfizer Inc Technical Analysis

Trend traders will want to observe that the strongest trend appears on the 30 day horizon; over that time period, price has been moving down. For another vantage point, consider that Pfizer Inc’s price has gone down 15 of the previous 30 trading days.

Overheard Around the Web

Here’s what one trader on StockTwits recently had to say in regards to PFE:

    [Long weekend read] Pfizer announces FDA approves sBLA for PANZYGA to treat CIDP Pfizer announced that the U.S. FDA has approved the supplemental Biologics License Application for PANZYGA to treat adult patients with a rare neurological disease of the peripheral nerves called chronic inflammatory demyelinating polyneuropathy. PANZYGA is the only intravenous immunoglobulin with two FDA-approved maintenance dosing options for CIDP, helping to meet the clinical needs of patients. PANZYGA can also be administered at infusion rates up to 12 mg/kg/min. Pfizer and Octapharma AG are parties to a license agreement pursuant to which Pfizer is granted rights to market and commercialize PANZYGA in the U.S. Octapharma retains exclusive rights to commercialize this product globally outside of the U.S.
    Read more at:

    View the full list of news/momentum plays on watch at :
    [No bias / position]
    [Find me at]